Date | : | January 23 (Tuesday), 2018. 9:00-17:10 |
Venue | : | Toshi Center Hotel Tokyo, Cosmos Hall I 2-4-1 Hirakawa-cho, Chiyoda-ku, Tokyo 102-0093, Japan. Tel: +81(0)3-3265-8211 (Map & Directions) |
Theme | : | The profound impact of epigenetics on cancer molecular medicine |
Organizing Committee: | ||
Chair Minoru Yoshida (RIKEN) |
||
Organizing Committee Members Hiroyuki Aburatani (University of Tokyo) Akihiro Ito (Tokyo University of Pharmacy and Life Sciences) Toshikazu Ushijima (National Cancer Center Research Institute) Yutaka Kondo (Nagoya University) Hiroyuki Seimiya (Japanese Foundation for Cancer Research) Shiro Akinaga (AccuRna, Inc.) |
||
Registration | : | Pre-registration required through Webpage or E-mail |
Fee: | JPY1,000 for members of the Association JPY3,000 for Non-members (Paid in cash at the Workshop reception desk) |
|
WS Secretariat | : | Center for Sustainable Resource Science, RIKEN 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. E-mail:13trw-jamttc@riken.jp |
Hiroyuki Osada (President, The Japanese Association for Molecular Target Therapy of Cancer)
1. | Dissecting cancer epigenome with iPS cell technology Yasuhiro Yamada (The Institute of Medical Science, The University of Tokyo; Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University) |
2. | Chemical biology of BRD4 antagonists Minoru Tanaka (Research Unit/Immunology & Inflammation, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation) |
3. | Precision cancer medicine based on gene aberrations: from kinases to chromatin regulators Takashi Kohno (Division of Genome Biology, National Cancer Center Research Institute) |
1. | Targeted epigenetic modifications: novel therapeutic strategies using pyrrole-imidazole polyamide for disease therapy Hiroki Nagase (Chiba Cancer Center Research Institute) |
2. | Molecular basis of endocrine therapy-resistant breast cancer and its therapeutic potential Mitsuyoshi Nakao (Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University) |
3. | Targeting long non-coding RNA as a novel approach for cancer treatment Yutaka Kondo (Division of Cancer Biology, Nagoya University Graduate School of Medicine) |
Chair: Minoru Yoshida Junji Matsui |
Translation of pre-clinical hypotheses of tumor sensitivity to EZH2 inhibition, in NHL & solid tumors, via clinical development of tazemetostat Stephen J. Blakemore (Epizyme, Inc.) |
1. | ChILT - an Immunoprecipitation-free Epigenome Profiling Technology Yasuyuki Ohkawa (Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University) |
2. | Epigenome editing and its potency Izuho Hatada (Laboratory of Genome Science, Institute for Molecular and Cellular Regulation, Gunma University) |
3. | Precision medicine by epigenetic biomarkers Toshikazu Ushijima (Division of Epigenomics, National Cancer Center Research Institute) |
15:10 - 15:30 Coffee break
1. | Challange to overcome targeted drug resistance in lung cancer by combined use of HDAC inhibitors Seiji Yano (Division of Medical Oncology , Cancer Research Institute, Kanazawa University) |
2. | HDAC inhibitor in clinical development for breast cancer and translational approaches Yozo Nishimura (Kyowa Hakko Kirin Co., Ltd.) |
3. | Development of cancer stem cell-targeted therapy based on inhibition of histone metyltransferase EZH1/2 and mutant IDH1 Issay Kitabayashi (Division of Hematological Malignancy, National Cancer Center Research Institute) |
Minoru Yoshida (Organizing Committee Chair, The 13th Translational Research Workshop)